Clinical safety oversight is the function that determines whether emerging risks in your study are identified in time to act. In an interventional clinical trial, the consequences of late or inconsistent safety signal detection include patient harm, regulatory action, emergency protocol amendments, and in severe cases, clinical hold.

The structural weakness in most outsourced safety models is the same as the structural weakness in outsourced monitoring: safety reports go to a vendor, the vendor produces output, the output goes to the sponsor, and by the time anyone has full context of a developing signal, the window for early intervention has often closed.

At APICES, safety oversight is conducted by physician-level medical monitors embedded in the study team. Safety data is reviewed as it accrues, not at reporting cycles. Issues that meet escalation thresholds are communicated immediately to the project manager and, where required, to the sponsor.

Medical Monitoring by Physician-Led Teams

Medical monitoring at APICES is conducted by qualified physicians with therapeutic-area experience. For oncology programmes, our medical monitors have oncology training. For rare disease programmes, the medical monitor is experienced in the specific patient population and the clinical context of the investigational product.

• Continuous adverse event review against the protocol-defined expected AE profile
• Serious adverse event (SAE) assessment and causality evaluation
• SUSAR identification, assessment, and regulatory reporting coordination
• Protocol-defined safety stopping rules monitoring and DSMB/DMC data package preparation
• SAE narrative review for clinical consistency before submission to EudraVigilance or FDA FAERS
• Development Safety Update Report (DSUR) and periodic safety update report (PSUR) authoring

Pharmacovigilance and Regulatory Safety Reporting

Regulatory safety reporting under the EU Clinical Trials Regulation (No 536/2014) and applicable GVP modules requires precise, timely execution. SUSAR submission timelines – 7 calendar days for fatal or life-threatening cases, 15 calendar days for all other cases – are non-negotiable.

APICES manages end-to-end SUSAR processing: AE assessment, causality evaluation, ICSR preparation, EudraVigilance submission, and onward distribution to participating EEA competent authorities and ethics committees. This is performed within the study safety team, not delegated to a separate pharmacovigilance unit with no operational context.

For sponsors requiring QPPV cover for European market authorizations or clinical trial sponsorship, APICES provides QPPV services including back-up arrangements and the EU Pharmacovigilance System Master File (PSMF).

DSMB and DMC Operations

• DSMB charter preparation and independent member coordination
• Blinded and unblinded data package preparation for DSMB meetings
• Statistical analysis of safety data for DSMB review, including interim safety analysis
• DSMB meeting minutes and recommendation documentation
• Integration of DSMB recommendations into the operational study plan

What You Can Expect

• Physician-level medical monitors with therapeutic-area experience
• Continuous adverse event and SAE review integrated with study operations
• SUSAR assessment, EudraVigilance submission, and competent authority distribution managed end-to-end
• DSUR and PSUR authoring integrated with the clinical study timeline
• DSMB/DMC support from charter preparation through recommendation integration
• QPPV cover for EU market authorization and clinical trial sponsorship

Frequently Asked Questions

What pharmacovigilance services does APICES provide?

ICSR processing, expedited reporting (SUSARs, DSURs, PSURs), aggregate-report writing, signal detection, risk-management plans (RMPs), QPPV cover, and post-marketing safety operations under EU GVP.

Are medical monitors physician-led?

Yes. Our medical monitors are physicians with therapeutic-area experience – most often oncology, rare disease, or immunology, depending on the programme.

Who handles SUSAR submissions to EU competent authorities?

APICES handles end-to-end: assessment, EudraVigilance submission, and onward distribution to participating EEA authorities and ethics committees, in line with EU CTR and GVP.

Do you support DSMB / DMC operations?

Yes. We facilitate independent data safety monitoring boards, prepare blinded and unblinded data packages, and manage charter and minutes through to study close-out.

Can APICES act as QPPV for a sponsor?

Yes. We provide QPPV cover for European market authorizations and clinical-trial sponsorship, including back-up arrangements.